Short answer
Zymeworks Inc. (ZYME) filed an 8-K current report with the SEC on September 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.03 (Creation of a Direct Financial Obligation), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). CVRs grant holders 80% of ampreloxetine licensing proceeds, $50M first-sale milestone, and 10% of qualifying net sales.
Zymeworks Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- CVRs grant holders 80% of ampreloxetine licensing proceeds, $50M first-sale milestone, and 10% of qualifying net sales
- CVR payments remain highly speculative, with no assurance of licensing, commercialization, or eventual distributions
- $350M senior secured financing funds merger consideration and CVR obligations, increasing leverage at 8.25% fixed interest
- Notes mature December 31, 2036, with quarterly interest and potential payment-in-kind accrual if collection-account funds are insufficient
- Debt secured by substantially all issuer and guarantor personal property, with restrictive covenants and change-of-control acceleration risk
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Item 2.01 references the Introductory Note and Item 1.01, indicating the acquisition or disposition details are disclosed elsewhere in the filing
- Investors should review Item 1.01 for transaction terms, consideration, assets transferred and expected strategic impact
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 covers financing obligations created under the Note Purchase Agreement
- Guaranty and Security Agreement indicates secured obligations and potential collateral claims
- Investors should review Item 1.01 for note amount, maturity, interest rate and collateral terms
Item 7.01 · Regulation FD Disclosure
- Merger closing announced September 23, 2026, marking completion of Zymeworks’ transformational transaction
- Investor conference call scheduled September 28 at 8:30 a.m. Eastern Time to discuss closing implications
- Expected strategic benefits include greater R&D investment flexibility and pursuit of additional opportunities
- Value drivers include future YUPELRI® royalties, TRELEGY® contingent milestones and zanidatamab commercialization
- Key execution risks: financing adjustments, milestone shortfalls, regulatory delays and uncertain product commercialization
Item EX-99.1 · Exhibit EX-99.1
- Acquisition of Theravance Biopharma completed, making Theravance part of Zymeworks
- Strategic shift toward diversified revenue from commercial assets, royalties, and internal R&D
- YUPELRI, TRELEGY royalty interests, Ziihera, and pasritamig highlighted as portfolio assets
- Investor conference call scheduled September 28 at 8:30 a.m. ET for final transaction details
- Key risks include financing, integration benefits, product approvals, and achievement of anticipated milestones
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zymeworks Inc. 8-K filings
Get the next ZYME 8-K as it lands
Follow ZYME for push alerts, or ask the research agent what this filing means.